DiscoverThe IMID ForumDiscussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis
Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

Update: 2025-11-13
Share

Description

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
Comments 
In Channel
Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2

Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2

2025-11-1617:02

Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

2025-11-1314:37

Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab

Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab

2025-11-0605:15

ACR 2025 Review Podcast

ACR 2025 Review Podcast

2025-11-0540:15

ACR Daily Highlights Day 4

ACR Daily Highlights Day 4

2025-10-2901:48

ACR Daily Highlights: Day 3

ACR Daily Highlights: Day 3

2025-10-2803:49

Pathways Modulating IMIDs: Webinar Highlights Podcast

Pathways Modulating IMIDs: Webinar Highlights Podcast

2025-10-2824:49

ACR Daily Highlights: Day 2

ACR Daily Highlights: Day 2

2025-10-2704:03

ACR Daily Highlights: Day 1

ACR Daily Highlights: Day 1

2025-10-2603:49

ACR 2025 Preview Podcast

ACR 2025 Preview Podcast

2025-10-2222:47

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

2025-10-0918:31

Author Interview: Doctor David Kellner, September 2025

Author Interview: Doctor David Kellner, September 2025

2025-10-0222:44

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

2025-09-2508:44

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

2025-09-1820:52

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

2025-09-0407:41

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

2025-08-2828:57

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

2025-08-1445:23

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

2025-08-0717:45

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

2025-07-3113:24

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

2025-07-1016:44

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

The Immune-Mediated Inflammatory Disease Forum